Liu Ming-Yue, Li Xi-Qing, Gao Tian-Hui, Cui Yao, Ma Ning, Zhou Yun, Zhang Guo-Jun
Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;; Department of Oncology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou 450003, China.
Department of Oncology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou 450003, China.
J Thorac Dis. 2016 Nov;8(11):3314-3322. doi: 10.21037/jtd.2016.11.75.
This study investigated the mechanism of drug resistance in non-small cell lung cancer (NSCLC) patients. We specifically studied whether long noncoding RNAs influence drug resistance in NSCLC to discover new therapeutic targets to increase the survival rate of drug-resistant NSCLC patients.
Tissue samples were collected from NSCLC patients, and total RNA was isolated for assessment of HOTAIR expression and drug resistance status. MTT assays, tumor sphere formation assays, and western blot were performed to cytologically determine the relationship between HOTAIR expression and cisplatin resistance, as well as to elucidate the potential molecular mechanism involved.
HOTAIR expression in tissues of drug-resistant NSCLC patients was higher than that of non-drug-resistant patients. HOTAIR expression was elevated in cisplatin-resistant cell strains (A549/CDDP), and reducing HOTAIR expression increased the sensitivity of A549/CDDP cells to cisplatin. In addition, overexpression of HOTAIR in A549 cells increased resistance to cisplatin. Tumor sphere formation assays showed that the volume of spheres formed by cell strains expressing elevated levels of HOTAIR was greater than that of cell strains with low expression. Western blot experiments showed that elevated expression of HOTAIR upregulated tumor stem cell-related biomarkers and HOTAIR expression was directly related to Klf4 expression.
Elevated HOTAIR expression is associated with drug resistance in NSCLC patients and is related to Klf4 upregulation, providing a new therapeutic target for drug-resistant NSCLC patients.
本研究调查了非小细胞肺癌(NSCLC)患者的耐药机制。我们专门研究了长链非编码RNA是否影响NSCLC的耐药性,以发现新的治疗靶点,提高耐药NSCLC患者的生存率。
收集NSCLC患者的组织样本,分离总RNA以评估HOTAIR表达和耐药状态。进行MTT试验、肿瘤球形成试验和蛋白质印迹法,以细胞学方式确定HOTAIR表达与顺铂耐药性之间的关系,并阐明其中潜在的分子机制。
耐药NSCLC患者组织中的HOTAIR表达高于非耐药患者。顺铂耐药细胞株(A549/CDDP)中HOTAIR表达升高,降低HOTAIR表达可增加A549/CDDP细胞对顺铂的敏感性。此外,A549细胞中HOTAIR的过表达增加了对顺铂的耐药性。肿瘤球形成试验表明,HOTAIR表达水平升高的细胞株形成的球体积大于低表达细胞株。蛋白质印迹实验表明,HOTAIR表达升高上调了肿瘤干细胞相关生物标志物,且HOTAIR表达与Klf4表达直接相关。
HOTAIR表达升高与NSCLC患者的耐药性相关,且与Klf4上调有关,为耐药NSCLC患者提供了新的治疗靶点。